Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer

Completed · Phase 1

Conditions studied: Colorectal Cancer, Diarrhea

In brief

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving irinotecan with celecoxib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when given with celecoxib in treating patients with unresectable or metastatic colorectal cancer.

Key facts

Study ID

NCT00084721

Run by

Roswell Park Cancer Institute

People needed

2

Starts

2005-03-01

Last updated by the study team

2013-01-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.